FORESEE PHARMACEUTICALS CO LTD has a total of 48 patent applications. It decreased the IP activity by 75.0%. Its first patent ever was published in 2005. It filed its patents most often in Australia, United States and EPO (European Patent Office). Its main competitors in its focus markets pharmaceuticals, organic fine chemistry and macromolecular chemistry and polymers are TARCIC NORA, AXOVANT SCIENCES GMBH and FLX BIO INC.
# | Country | Total Patents | |
---|---|---|---|
#1 | Australia | 10 | |
#2 | United States | 9 | |
#3 | EPO (European Patent Office) | 5 | |
#4 | Canada | 4 | |
#5 | China | 4 | |
#6 | Brazil | 3 | |
#7 | Republic of Korea | 3 | |
#8 | Israel | 2 | |
#9 | Mexico | 2 | |
#10 | Singapore | 2 | |
#11 | Taiwan | 2 | |
#12 | New Zealand | 1 | |
#13 | Russian Federation | 1 |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Therapeutic chemical compounds | |
#3 | Nanostructure applications | |
#4 | Polysaccharides | |
#5 | Heterocyclic compounds | |
#6 | Fermentation | |
#7 | Organic chemistry methods |
# | Name | Total Patents |
---|---|---|
#1 | Li Yuhua | 36 |
#2 | Huang Chiating | 10 |
#3 | Mao John | 10 |
#4 | Guarino Andrew | 9 |
#5 | Lee Chen-Chang | 8 |
#6 | Chien Benjamin | 7 |
#7 | Yang Chia-Ying | 5 |
#8 | Yuhua Li | 5 |
#9 | Lin Chih-Ying | 5 |
#10 | Guarino Andrew J | 5 |
Publication | Filing date | Title |
---|---|---|
KR20210004939A | Ester of dihydrotetrabenazine | |
US2020345724A1 | Pharmaceutical composition for sustained release delivery of buprenorphine | |
KR20210005542A | Pharmaceutical composition with selected release period | |
CA3034032A1 | Compositions comprising inhibitors of macrophage elastase and cyclodextrin | |
US2019054178A1 | Pharmaceutical composition and methods of uses | |
TW201714622A | Pharmaceutical composition with improved stability | |
AU2009212373A1 | Non-polymeric compositions for controlled drug delivery | |
AU2005277432A1 | 5-[3-(4-benzyloxyphenylthio)-fur-2-yl]-imidazolidin-2, 4-dione and analogues as inhibitors of macrophage elastase |